- Conditions
- Terminally Ill, Histologically-confirmed Advanced Cancer, Pain, Intractable
- Interventions
- Substance P-Saporin
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- La Jolla, California • Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 708
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cervical Cancer, Radiation Toxicity
- Interventions
- Amifostine trihydrate, Cisplatin, Intracavitary brachytherapy, External beam radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 17
- States / cities
- Jacksonville, Florida • Jacksonville Beach, Florida • Jascksonville, Florida + 11 more
- Conditions
- Influenza
- Interventions
- Placebo, Trivalent Inactivated Influenza
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 21 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Osteoarthritis, Osteoarthritis Thumb Base Joint, Carpometacarpal Osteoarthritis, Thumb
- Interventions
- CTM, Placebo
- Device · Other
- Lead sponsor
- Indiana Hand to Shoulder Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, epratuzumab, cytarabine, prednisone, pegaspargase, dexrazoxane hydrochloride, methotrexate, etoposide, cyclophosphamide, leucovorin calcium, filgrastim
- Drug · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 2 Years to 31 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Loma Linda, California • Long Beach, California + 36 more
- Conditions
- Metastatic Prostate Cancer, Androgen Deprivation Therapy
- Interventions
- GnRH agonist
- Drug
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Discogenic Pain
- Interventions
- High yield pure PRP, Placebo, ProPlaz PPC
- Device · Other
- Lead sponsor
- Neurological Associates of West Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 7
- States / cities
- Campbell, California • Santa Monica, California • Peachtree City, Georgia + 2 more
- Conditions
- Sickle Cell Anemia
- Interventions
- Regadenoson, Placebo
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 10 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 12
- States / cities
- Oakland, California • Chicago, Illinois • Baltimore, Maryland + 7 more
- Conditions
- Postoperative Pain
- Interventions
- Erector Spinae Plane block, Quadratus Lumborum Block
- Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Milk Allergy
- Interventions
- Placebo for omalizumab, Omalizumab, Milk powder
- Biological · Drug
- Lead sponsor
- Hugh A Sampson, MD
- Other
- Eligibility
- 7 Years to 35 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 3
- States / cities
- Stanford, California • Baltimore, Maryland • New York, New York
- Conditions
- Anterior Cruciate Ligament (ACL) Tear
- Interventions
- Single-injection sciatic PNB, Continuous sciatic PNB
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Healthy Participants
- Interventions
- AG-236, Placebo
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- NLRC4-MAS, XIAP Deficiency
- Interventions
- Tadekinig alfa, 0.9% sodium chloride
- Drug · Other
- Lead sponsor
- AB2 Bio Ltd.
- Industry
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 6
- States / cities
- La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Autologous Dendritic Cell-Adenovirus CCL21 Vaccine, Pembrolizumab
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Graft vs Host Disease
- Interventions
- Begelomab, Conventional Second-line Treatment
- Biological
- Lead sponsor
- Adienne SA
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 10
- States / cities
- Duarte, California • Westwood, Kansas • Boston, Massachusetts + 7 more
- Conditions
- Fractures, Comminuted, Surgical Wound Dehiscence, Necrosis
- Interventions
- ICG (Indocyanine Green)
- Drug
- Lead sponsor
- Louisiana State University Health Sciences Center Shreveport
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Shreveport, Louisiana
- Conditions
- Bacterial Infections
- Interventions
- 11C-Trimethoprim
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Pancreatitis, Diabetes Mellitus
- Interventions
- Closed Loop Insulin
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 21 Years to 64 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- RUNX1 Familial Platelet Disorder
- Interventions
- G-CSF (filgrastim or biosimilar), Apheresis, Plerixafor
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Obesity
- Interventions
- Semaglutide
- Drug
- Lead sponsor
- United States Army Research Institute of Environmental Medicine
- Federal
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Natick, Massachusetts
- Conditions
- Lumbar Spinal Stenosis
- Interventions
- Individualized report
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Psoriatic Arthritis
- Interventions
- Secukinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 22
- States / cities
- Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 18 more
- Conditions
- Macromastia, Post-operative Pain
- Interventions
- Marcaine 0.25 % Injectable Solution, Saline
- Drug
- Lead sponsor
- Connecticut Children's Medical Center
- Other
- Eligibility
- 13 Years to 25 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Farmington, Connecticut • Hartford, Connecticut
- Conditions
- Lymphoma
- Interventions
- 90-Y-ibritumomab tiuxetan, rituximab, indium In 111 ibritumomab tiuxetan
- Biological · Radiation
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia